^
Association details:
| Biomarker: | APP-NRG1 fusion |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NRG1 fusion-positive gastrointestinal tumours: Afatinib as a novel potential treatment option
Excerpt:
Following intolerance to first -line treatment (gemcitabine + nab -paclitaxel), WGTA of tissue from a liver biopsy revealed a complex structural rearrangement leading to fusion of NRG1 (exons 6/7) and APP (between exons 15 and 16), indicating potential susceptibility to afatinib.
